Systematic identification of novel SLE related autoantibodies responsible for type I IFN production in human plasmacytoid dendritic cells

Cellular Immunology

Volumn 284, Issue 1-2, 2013, Pages 119-128

  Kassim, Sadik H ^a   Jordan, Jarrat ^a   Schreiter, Jessica ^a   Adhikarakunnathu, Sreedevi ^a   Baribaud, Fred ^a   San Mateo, Lani ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Autoimmune; Innate immunity; Plasmacytoid dendritic cells; Protein array; SLE; Type I interferons

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CHEMOKINE RECEPTOR CCR7; COMPLEMENTARY DNA; CPG OLIGODEOXYNUCLEOTIDE; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NUCLEIC ACID BINDING PROTEIN; PROTEIN P100;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREEZE THAWING; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

AUTOIMMUNE; INNATE IMMUNITY; PLASMACYTOID DENDRITIC CELLS; PROTEIN ARRAY; SLE; TYPE I INTERFERONS;

ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; CELL LINE; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEIN ARRAY ANALYSIS;

EID: 84883023691     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.07.017     Document Type: Article

References (52)

1. Sigurdsson S., Göring H.H.H., Kristjansdottir G., Milani L., Nordmark G., Sandling J.K., et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 [IRF5] reveals a novel 5bp length polymorphism as strong risk factor for systemic lupus erythematosus. Human Molecular Genetics 2008, 17(6):872-881.
2. Niewold T.B., Swedler W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clinical Rheumatology 2005, 24(2):178-181.
3. Ioannou Y., Isenberg D.A. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis & Rheumatism 2000, 43(7):1431-1442.
4. Dall'Era M.C., Cardarelli P.M., Preston B.T., Witte A., Davis J.C. Type I interferon correlates with serological and clinical manifestations of SLE. Annals of the Rheumatic Diseases 2005, 64(12):1692-1697.
5. Bengtsson A.A., Sturfelt G., Truedsson L., Blomberg J., Alm G., Vallin H., et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000, 9(9):664-671.
6. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001, 294(5546):1540-1543.
7. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nature Immunology 2002, 3(9):822-829.
8. Yao Y., Richman L., Higgs B.W., Morehouse C.A., De los Reyes M., Brohawn P., et al. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis & Rheumatism 2009, 60(6):1785-1796.
9. Santiago-Raber M.-L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. The Journal of Experimental Medicine 2003, 197(6):777-788.
10. Mathian A., Weinberg A., Gallegos M., Banchereau J., Koutouzov S. IFN-α induces early lethal lupus in preautoimmune [New Zealand black×New Zealand white]F1 but not in BALB/c mice. The Journal of Immunology 2005, 174(5):2499-2506.
11. Mathian A., Weinberg A., Gallegos M., Banchereau J., Koutouzov S. IFN-α induces early lethal lupus in preautoimmune [New Zealand black×New Zealand white]F1 but not in BALB/c mice. The Journal of Immunology 2005, 174(5):2499-2506.
12. Yao Y., Higgs B.W., Morehouse C., de los Reyes M., Trigona W., Brohawn P., et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Human Genomics and Proteomics 2009, 1(1).
13. Braunstein I., Klein R., Okawa J., Werth V.P. The IFN-regulated gene signature is elevated in SCLE and DLE and correlates with CLASI score. British Journal of Dermatology 2012, 166(5):971-975.
14. Higgs B.W., Liu Z., White B., Zhu W., White W.I., Morehouse C., et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Annals of the Rheumatic Diseases 2011, 70(11):2029-2036.
15. Toukap A.N., Galant C., Theate I., Maudoux A.L., Lories R.J.U., Houssiau F.A., et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis & Rheumatism 2007, 56(5):1579-1588.
16. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proceedings of the National Academy of Sciences 2003, 100(5):2610-2615.
17. Kirou K.A., Lee C., George S., Louca K., Peterson M.G.E., Crow M.K. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis & Rheumatism 2005, 52(5):1491-1503.
18. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. New England Journal of Medicine 1979, 301(1):5-8.
19. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New England Journal of Medicine 2003, 349(16):1526-1533.
20. Lövgren T., Eloranta M.-L., Kastner B., Wahren-Herlenius M., Alm G.V., Rönnblom L. Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis & Rheumatism 2006, 54(6):1917-1927.
21. Weckerle C.E., Franek B.S., Kelly J.A., Kumabe M., Mikolaitis R.A., Green S.L., et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis & Rheumatism 2011, 63(4):1044-1053.
22. Lövgren T., Eloranta M.-L., Båve U., Alm G.V., Rönnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis & Rheumatism 2004, 50(6):1861-1872.
23. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25(3):383-392.
24. Obermoser G., Pascual V. The interferon-α signature of systemic lupus erythematosus. Lupus 2010, 19(9):1012-1019.
25. Elkon K., Casali P. Nature and functions of autoantibodies. Nature Clinical Practice Rheumatology 2008, 4(9):491-498.
26. Michaud G.A., Salcius M., Zhou F., Bangham R., Bonin J., Guo H., et al. Analyzing antibody specificity with whole proteome microarrays. Nature Biotechnology 2003, 21(12):1509-1512.
27. Lueking A., Possling A., Huber O., Beveridge A., Horn M., Eickhoff H., et al. A nonredundant human protein chip for antibody screening and serum profiling. Molecular & Cellular Proteomics 2003, 2(12):1342-1349.
28. Rönnblom L., Alm G.V., Eloranta M.-L. The type I interferon system in the development of lupus. Seminars in Immunology 2011, 23(2):113-121.
29. Vallin Blomberg. Alm, Cederblad, RÖNnblom. Patients with systemic lupus erythematosus [SLE] have a circulating inducer of interferon-alpha [IFN-α] production acting on leucocytes resembling immature dendritic cells. Clinical & Experimental Immunology 1999, 115(1):196-202.
30. Vallin H., Perers A., Alm G.V., Rönnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. The Journal of Immunology 1999, 163(11):6306-6313.
31. Båve U., Magnusson M., Eloranta M.-L., Perers A., Alm G.V., Rönnblom L. FcγRIIa is expressed on natural IFN-α-producing cells [plasmacytoid dendritic cells] and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. The Journal of Immunology 2003, 171(6):3296-3302.
32. Tian J., Avalos A.M., Mao S.-Y., Chen B., Senthil K., Wu H., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nature Immunology 2007, 8(5):487-496.
33. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. The Journal of Experimental Medicine 2005, 202(11):1575-1585.
34. Patole P.S., Gröne H.-J., Segerer S., Ciubar R., Belemezova E., Henger A., et al. Viral double-stranded RNA aggravates lupus nephritis through toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. Journal of the American Society of Nephrology 2005, 16(5):1326-1338.
35. Kono D.H., Haraldsson M.K., Lawson B.R., Pollard K.M., Koh Y.T., Du X., et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proceedings of the National Academy of Sciences 2009, 106(29):12061-12066.
36. Hua J., Kirou K., Lee C., Crow M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis & Rheumatism 2006, 54(6):1906-1916.
37. Båve U., Alm G.V., Rönnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. The Journal of Immunology 2000, 165(6):3519-3526.
38. Kousaka K., Kiyonari H., Oshima N., Nagafuchi A., Shima Y., Chisaka O., et al. Slingshot-3 dephosphorylates ADF/cofilin but is dispensable for mouse development. Genesis 2008, 46(5):246-255.
39. Magnuson N.S., Wang Z., Ding G., Reeves R. Why target PIM1 for cancer diagnosis and treatment?. Future Oncology 2010, 6(9):1461-1478.
40. Shin Y.S., Takeda K., Shiraishi Y., Jia Y., Wang M., Jackson L., et al. Inhibition of Pim1 kinase activation attenuates allergen-induced airway hyperresponsiveness and inflammation. American Journal of Respiratory Cell and Molecular Biology 2012, 46(4):488-497.
41. Griseri P., Vos Y., Giorda R., Gimelli S., Beri S., Santamaria G., et al. Complex pathogenesis of Hirschsprung's disease in a patient with hydrocephalus, vesico-ureteral reflux and a balanced translocation t[3;17][p12;q11]. European Journal of Human Genetics 2008, 17(4):483-490.
42. Lee M.H., Lin S.R., Chang J.Y., Schultz L., Heath J., Hsu L.J., et al. TGF-[beta] induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid [beta] plaques in Alzheimer's disease. Cell Death and Disease 2010, 1:e110.
43. Morgan A.R., Turic D., Jehu L., Hamilton G., Hollingworth P., Moskvina V., et al. Association studies of 23 positional/functional candidate genes on chromosome 10 in late-onset Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2007, 144B(6):762-770.
44. Stepanova L., Leng X., Parker S.B., Harper J.W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes & Development 1996, 10(12):1491-1502.
45. Miyata Y. Protein kinase CK2 in health and disease. Cellular and Molecular Life Sciences 2009, 66(11):1840-1849.
46. Bertoli A., Vilá L.M., Reveille J.D., Alarcón G.S. Systemic lupus erythematosus in a multiethnic US Cohort [LUMINA]: LXI. Value of C-reactive protein as a marker of disease activity and damage. The Journal of Rheumatology 2008, 35(12):2355-2358.
47. Sontheimer R.D., Maddison P.J., Reichlin M., Jordon R.E., Stastny P., Gilliam J.N. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Annals of Internal Medicine 1982, 97(5):664-671.
48. Cooper G.S., Parks C.G., Treadwell E.L., St Clair E.W., Gilkeson G.S., Cohen P.L., et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002, 11(3):161-167.
49. Zonana-Nacach A., Roseman J.M., McGwin G., Friedman A.W., Baethge B.A., Reveille J.D. Systemic lupus erythematosus in three ethnic groups. VI: factors associated with fatigue within 5years of criteria diagnosis. Lupus 2000, 9(2):101-109.
50. Alarcón G.S., Friedman A.W., Straaton K.V., Moulds J.M., Lisse J., Bastian H.M., et al. Systemic lupus erythematosus in three ethnic groups: III A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999, 8(3):197-209.
51. Quinn M.A., Gough A.K.S., Green M.J., Devlin J., Hensor E.M.A., Greenstein A., et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology 2006, 45(4):478-480.
52. van Venrooij W.J., van Beers J.J.B.C., Pruijn G.J.M. Anti-CCP antibodies: the past, the present and the future. Nature Reviews Rheumatology 2011, 7(7):391-398.